IP Library › Granted Patent US 8,440,813
Granted Patent B2
US 8,440,813 · App. 12/522,892 · Granted May 14, 2013

Antiviral nucleoside analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,813
App. No.
12/522,892
Granted
May 14, 2013
Kind
B2
Abstract

The invention provides compounds of Formula (I), as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents.

Claims (2)

1. A compound of formula (11):

or a pharmaceutically acceptable salt thereof.

Assignments (6)
SECURITY INTEREST Recorded Jan 23, 2026
From: BIOCRYST PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074485/0651 →
RELEASE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063362/0550 →
RELEASE OF SECURITY INTEREST Recorded Apr 6, 2023
From: MIDCAP FINANCIAL TRUST
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 063348/0762 →
SECURITY INTEREST Recorded Dec 17, 2020
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 054800/0634 →
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 054774/0446 →
SECURITY INTEREST Recorded Sep 26, 2016
From: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 039858/0967 →